| [1] |
Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto's thyroiditis and thyroid cancer in 64,628 patients[J]. Front Oncol, 2017, 7: 53.
|
| [2] |
Azizi G, Keller JM, Lewis M, et al. Association of Hashimoto's thyroiditis with thyroid cancer[J]. Endocr Relat Cancer, 2014, 21(6): 845-852.
|
| [3] |
Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders[J]. Autoimmun Rev, 2015, 14(2): 174-180.
|
| [4] |
Dvorkin S, Robenshtok E, Hirsch D, et al. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis[J]. J Clin Endocrinol Metab, 2013, 98(6): 2409-2414.
|
| [5] |
Xu S, Huang H, Qian J, et al. Prevalence of Hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes[J]. JAMA Netw Open, 2021, 4(7): e2118526.
|
| [6] |
Felicetti F, Catalano MG, Fortunati N. Thyroid autoimmunity and cancer[J]. Front Horm Res, 2017, 48: 97-109.
|
| [7] |
Pagano L, Mele C, Sama MT, et al. Thyroid cancer phenotypes in relation to inflammation and autoimmunity[J]. Front Biosci (Landmark Ed), 2018, 23(12): 2267-2282.
|
| [8] |
Guarino V, Castellone MD, Avilla E, et al. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1): 94-102.
|
| [9] |
Anderson NM, Simon MC. The tumor microenvironment[J]. Curr Biol, 2020, 30(16): R921-R925.
|
| [10] |
Muzza M, Degl'Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies[J]. Clin Endocrinol (Oxf), 2010, 72(5): 702-708.
|
| [11] |
Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis[J]. Am J Cancer Res, 2012, 2(3): 286-297.
|
| [12] |
Varricchi G, Loffredo S, Marone G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20(16): 3934.
|
| [13] |
Visciano C, Liotti F, Prevete N, et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway[J]. Oncogene, 2015, 34(40): 5175-5186.
|
| [14] |
Pani F, Yasuda Y, Di Dalmazi G, et al. Pre-existing thyroiditis ameliorates papillary thyroid cancer: insights from a new mouse model[J]. Endocrinology, 2021, 162(10): bqab144.
|
| [15] |
Rotondi M, Coperchini F, Pignatti P, et al. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: A first step toward a differentiation between autoimmune and tumor-related inflammation?[J]. J Clin Endocrinol Metab, 2013, 98(1): 308-313.
|
| [16] |
Ehlers M, Schott M. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?[J]. Trends Endocrinol Metab, 2014, 25(12): 656-664.
|
| [17] |
Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene[J]. Proc Natl Acad Sci U S A, 2005, 102(41): 14825-14830.
|
| [18] |
Russell JP, Shinohara S, Melillo RM, et al. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors[J]. Oncogene, 2003, 22(29): 4569-4577.
|
| [19] |
Puxeddu E, Knauf JA, Sartor MA, et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response[J]. Endocr Relat Cancer, 2005, 12(2): 319-334.
|
| [20] |
Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation[J]. Autoimmun Rev, 2020, 19(10): 102649.
|
| [21] |
Sulaieva O, Chernenko O, Selesnov O, et al. Mechanisms of the impact of Hashimoto thyroiditis on papillary thyroid carcinoma progression: relationship with the tumor immune microenvironment[J]. Endocrinol Metab (Seoul), 2020, 35(2): 443-455.
|
| [22] |
Pan J, Ye F, Yu C, et al. Papillary Thyroid carcinoma landscape and its immunological link with Hashimoto thyroiditis at single-cell resolution[J]. Front Cell Dev Biol, 2021, 9: 758339.
|
| [23] |
Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA methyltransferase inhibition upregulates MHC-Ⅰ to potentiate cytotoxic T lymphocyte responses in breast cancer[J]. Nat Commun, 2018, 9(1): 248.
|
| [24] |
Han LT, Hu JQ, Ma B, et al. IL-17A increases MHC class Ⅰ expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis[J]. Diagn Pathol, 2019, 14(1): 52.
|
| [25] |
Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNγ in cancer progression: A role of PD-L1 induction in the determination of pro- and antitumor immunity[J]. Clin Cancer Res, 2016, 22(10): 2329-2334.
|
| [26] |
French JD, Kotnis GR, Said S, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2012, 97(6): E934-E943.
|
| [27] |
Hu JQ, Lei BW, Wen D, et al. IL-2 enhanced MHC class Ⅰexpression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro[J]. J Cancer, 2020, 11(14): 4250-4260.
|
| [28] |
Lu ZW, Hu JQ, Liu WL, et al. IL-10 Restores MHC class Ⅰexpression and interferes with immunity in papillary thyroid cancer with Hashimoto thyroiditis[J]. Endocrinology, 2020, 161(10): bqaa062.
|
| [29] |
Hashemi Goradel N, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: A review[J]. J Cell Physiol, 2019, 234(5): 5683-5699.
|
| [30] |
Dong S, Xie XJ, Xia Q, et al. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis[J]. Am J Cancer Res, 2019, 9(8): 1786-1795.
|
| [31] |
Parvathareddy SK, Siraj AK, Annaiyappanaidu P, et al. Prognostic significance of COX-2 overexpression in BRAF-mutated middle eastern papillary thyroid carcinoma[J]. Int J Mol Sci, 2020, 21(24): 9498.
|
| [32] |
李中勇, 李乐. 桥本甲状腺炎合并甲状腺乳头状癌中环氧化酶-2、Survivin和胸腺基质淋巴细胞的表达及临床意义[J]. 中国耳鼻咽喉头颈外科, 2019, 26(6): 298-301.
|
| [33] |
Xu J, Ding K, Mu L, et al. Hashimoto's thyroiditis: A "double-edged sword" in thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2022, 13: 801925.
|
| [34] |
Rotondi M, Groppelli G, Croce L, et al. Patients with chronic autoimmune thyroiditis are not at higher risk for developing clinically overt thyroid cancer: A 10-year follow-up study[J]. Eur J Endocrinol, 2020, 183(3): 317-323.
|
| [35] |
Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer[J]. Oncotarget, 2016, 7(13): 17194-17211.
|
| [36] |
Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors[J]. Cancer Treat Rev, 2016, 42: 47-55.
|